Likar.Info Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: fi rst results of the ATAC randomised trial. Lancet 2002; 359: 2131–39. 3. Goetz MP, Knox K, Suman VJ, ...
MarketWatch (press release) ... of the European Union to treat postmenopausal women with advanced hormone receptor-positive, HER2 negative (advanced HR+/HER2 negative)...
MarketWatch ... of the European Union to treat postmenopausal women with advanced hormone receptor-positive, HER2 negative (advanced HR+/HER2 negative) breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole (2).
MarketWatch (press release) ... for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2 negative breast cancer (advanced HR+/HER2 negative breast cancer) in combination with exemestane after failure of treatment with letrozole or anastrozole . and more »
MarketWatch ... of the European Union to treat postmenopausal women with advanced hormone receptor-positive, HER2 negative (advanced HR+/HER2 negative) breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole (2).
MarketWatch ... of the European Union to treat postmenopausal women with advanced hormone receptor-positive, HER2 negative (advanced HR+/HER2 negative) breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole (2).
MarketWatch ... of the European Union to treat postmenopausal women with advanced hormone receptor-positive, HER2 negative (advanced HR+/HER2 negative) breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole (2).
pharmabiz.com ... for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2 negative breast cancer (advanced HR+/HER2 negative breast cancer) in combination with exemestane after failure of treatment with letrozole or anastrozole .
Wall Street Journal (press release) ... limited to, amiodarone, disopyramide, procainamide, quinidine, and sotalol) and other drugs that may prolong the QT interval (including, but not limited to, chloroquine, clarithromycin, haloperidol, methadone, moxifloxacin , and pimozide) should be ... and more »
